PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Etiology • Epidemiology • Symptoms • Diagnosis and testing • Treatment • Prognosis • Economic burden • Reimbursement scenario PART 06: Pipeline analysis • Z-206 • MD-0901 • TP05 • Stelara • Etrolizumab • Xeljanz • HMPL-004 • Kappaproct • AJG511 • AJM300 PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by molecule type • Biologics • Small molecules • Biologics segment in ulcerative colitis drugs market • Small molecules segment in ulcerative colitis drugs market PART 09: Market segmentation by dosage form • Solid • Liquid PART 10: Market segmentation by route of administration • Oral • Parenteral PART 11: Geographical segmentation • Global ulcerative colitis drugs market by geography 2015-2020 • Ulcerative colitis drugs market in Americas • Ulcerative colitis drugs market in EMEA • Ulcerative colitis drugs market in APAC PART 12: Market drivers • Increase in patient assistance programs • High unmet needs • Tentative approval of candidates in pipeline PART 13: Impact of drivers PART 14: Market challenges • High cost of drugs • Patent expiries • Adverse effects of drugs • Unknown disease etiology PART 15: Impact of drivers and challenges PART 16: Market trends • Growing public awareness • Rising use of biologics • Emergence of biosimilars • Strategic alliances PART 17: Vendor landscape • Competitive scenario • Market share analysis 2015 • AbbVie • Janssen Biotech • Merck • Takeda Pharmaceuticals • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Causes of ulcerative colitis Exhibit 03: Symptoms of ulcerative colitis Exhibit 04: Diagnostic approach for ulcerative colitis Exhibit 05: Treatment options for ulcerative colitis Exhibit 06: Treatment guidelines of ulcerative colitis based on severity Exhibit 07: Surgical procedures to treat ulcerative colitis Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions) Exhibit 10: Snapshot of global ulcerative colitis drugs market Exhibit 11: Five forces analysis Exhibit 12: Global ulcerative colitis drugs market by molecule type Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015 Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions) Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions) Exhibit 16: Global ulcerative colitis drugs market by dosage form Exhibit 17: Global ulcerative colitis drugs market by route of administration Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015 Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions) Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions) Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions) Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions) Exhibit 23: Impact of drivers Exhibit 24: Impact of drivers and challenges Exhibit 25: Global ulcerative colitis drugs market share analysis 2015 Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions) Exhibit 27: AbbVie: Product segmentation by revenue 2014 Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions) Exhibit 29: AbbVie: Geographical segmentation by revenue 2014 Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions) Exhibit 31: AbbVie: Key takeaways Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions) Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions) Exhibit 34: Janssen Biotech: Key takeaways Exhibit 35: Merck: Business segmentation by revenue 2014 Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 37: Merck: Geographical segmentation by revenue 2014 Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions) Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions) Exhibit 40: Merck: Key takeaways Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014 Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions) Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014 Exhibit 44: Takeda Pharmaceuticals: Key takeaways

AbbVie, Janssen Biotech, Merck, Takeda Pharmaceuticals, Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, Zeria Pharmaceutical.